STAT

3 issues to watch in global health in 2018

What global health stories will we tell about 2018? The crystal ball is cloudy, but the haze parted long enough for us to discern a few things.

As 2018 begins, STAT reporters are taking a look at the stories they’re most eager to track this year. Find all our “three to watch” series here

Some years there’s a single global health story that dominates the headlines, like Ebola in 2014 or Zika in 2016. But 2017 wasn’t one of those years.

There were a number of big stories, and big challenges. A devastating in Yemen. An alarming epidemic of in Madagascar. The spread of in Syria, which paralyzed 74 children who were already struggling to survive the country’s relentless and bloody civil war. On a happier note, the World Health Organization got a, Tedros Adhanom Ghebreyesus of Ethiopia.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT1 min read
STAT+: Nuclear Regulatory Commission Advisers Beset By Conflicts Of Interest, Report Finds
Advisers to the Nuclear Regulatory Commission, a U.S. government agency tasked with ensuring the safe use of radioactive materials, were beset by conflicts of interest, report finds

Related Books & Audiobooks